Browsing: biotechnology

Presidential sessions at top cancer meetings typically feature practice-changing clinical trials, detailed in front of thousands of global experts packed into rooms so cavernous they merit their own ZIP codes. But last year, at the most important European oncology conference, one slot was reserved for a presentation of early results from a German biotech’s study…

Billionaire Mark Cuban has spent the last five years trying to make generic drugs like chemotherapy and antifungal ointment cheaper for Americans. But earlier this year, a very different type of medicine began arriving at his Dallas factory. 

Roivant and its spinout Priovant said Wednesday that their immune-modifying pill Lisraya was more effective than placebo in treating the inflammatory eye disease non-infectious uveitis.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Amid ongoing angst over prescription drug prices, a new analysis found the median net price for 202 newly launched medicines, when adjusted for inflation and manufacturer discounts, rose by 35% to $257,000 in 2025 from $190,000 in 2022.

This essay contains spoilers for “You Can See Everything,” Nathan Fielder’s new film about Theranos founder Elizabeth Holmes.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

This essay contains spoilers for “You Can See Everything,” Nathan Fielder’s new film about Theranos founder Elizabeth Holmes.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.